Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

71%

5 of 7 completed trials have results

Key Signals

3 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

N/A

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02000687Recruiting

Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss

Role: lead

NCT01999374Recruiting

Long Term Follow up of Recipients of Functional Islet Allografts

Role: lead

NCT01999361Not ApplicableRecruiting

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Role: lead

NCT03406897Phase 1Completed

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

Role: lead

NCT02213003Phase 1Completed

Allogeneic Islet Cells Transplanted Onto the Omentum

Role: lead

NCT00306098Phase 2Completed

Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression

Role: lead

NCT02004964Completed

Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation

Role: lead

NCT01786707Phase 1Completed

Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus

Role: lead

NCT00315627Phase 2Completed

Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation

Role: lead

NCT00315588Phase 2Completed

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

Role: lead

All 10 trials loaded